Dr. Myron Weisfeldt
Dr. Myron Weisfeldt is University Distinguished Service Professor at Johns Hopkins School of Medicine following a 13 year tenure as Chair of the Department of Medicine at Johns Hopkins. This single Department receives $200 Million per year in external research support. He is currently business and investment consultant at Johns Hopkins and leads an international network performing research in man on resuscitation from cardiac arrest and severe traumatic injury.
Dr. Weisfeldt received a B.A. and MD from the Johns Hopkins University. He trained in Cardiology at the Massachusetts General Hospital and the National Institutes of Health. From 1991 to 2001, he was Chairman of the Department of Medicine and Samuel Bard Professor of Medicine at the Columbia University College of Physicians and Surgeons and Director of the Medical Service at the Columbia-Presbyterian Campus of the New York Presbyterian Hospital. From 1975 to 1991, he was Director of the Cardiology Division at the Johns Hopkins University School of Medicine. Dr. Weisfeldt was Chairman of the Cardiology Advisory Board of the National Heart Lung and Blood Institute from 1987 to 1990 and held the position of President of the American Heart Association in 1990. He is a member of the Institute of Medicine of the National Academy of Sciences now called the National Academy of Medicine. His research interests have included heart function, age changes in the heart and circulation, and cardiopulmonary resuscitation.
Dr Weisfeldt’s accomplishments include a major role in the first implantation of automatic implantable defibrillators in human beings. He was the senior project investigator for the study which led to the approval by the FDA of TPA to dissolve the clot causing acute myocardial infarction. He lead the effort of the American Heart Association to develop and test the Automatic External Defibrillators for bystander use that are now seen in essentially all airports and many public location in the United States. He was among the study leaders of the clinical trial that established the value of Public Access Defibrillation to increase survival from sudden cardiac arrest.
In 2003 he was appointed by the National Heart, Lung and Blood Institute to be the Study Chair for a large-scale ongoing clinical trials network to conduct randomized definitive trials of devices, drugs and other therapies for out-of-hospital cardiac arrest and severe traumatic injury. This network is in its 11th year and has additional support from the US Department of Defense, Canadian Health Agencies, Defense Canada, and the American Heart Association. It does research in the Emergency Medical Systems in 7 US cities and 3 Canadian cites or regions. This research is conducted under the rules of waiver of informed consent.